X4 Pharmaceuticals, Inc Quarterly Debt-to-equity in % from Q3 2018 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
X4 Pharmaceuticals, Inc quarterly Debt-to-equity history and growth rate from Q3 2018 to Q2 2024.
  • X4 Pharmaceuticals, Inc Debt-to-equity for the quarter ending June 30, 2024 was 200 %, a 64% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 200 +78.2 +64% Jun 30, 2024
Q1 2024 224 +106 +89.6% Mar 31, 2024
Q4 2023 160 +51.5 +47.4% Dec 31, 2023
Q3 2023 140 +40.7 +40.8% Sep 30, 2023
Q2 2023 122 +25.7 +26.6% Jun 30, 2023
Q1 2023 118 +41.4 +54% Mar 31, 2023
Q4 2022 108 +43.6 +67.2% Dec 31, 2022
Q3 2022 99.6 +37.1 +59.5% Sep 30, 2022
Q2 2022 96.5 +40.2 +71.2% Jun 30, 2022
Q1 2022 76.6 +26.9 +54% Mar 31, 2022
Q4 2021 64.9 +21.9 +50.9% Dec 31, 2021
Q3 2021 62.4 +29.1 +87.4% Sep 30, 2021
Q2 2021 56.4 +25.2 +81% Jun 30, 2021
Q1 2021 49.7 +18 +56.9% Mar 31, 2021
Q4 2020 43 +3.37 +8.5% Dec 31, 2020
Q3 2020 33.3 -62.7 -65.3% Sep 30, 2020
Q2 2020 31.1 +658 Jun 30, 2020
Q1 2020 31.7 +85.5 Mar 31, 2020
Q4 2019 39.6 +71.2 Dec 31, 2019
Q3 2019 96 +133 Sep 30, 2019
Q2 2019 -626 Jun 30, 2019
Q1 2019 -53.8 Mar 31, 2019
Q4 2018 -31.6 Dec 31, 2018
Q3 2018 -36.7 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.